^
Association details:
| Biomarker: | YAP1 underexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients
Published date:
01/25/2023
Excerpt:
21 patients whoever received atezolizumab plus etoposide/carboplatin (ECT) regimen....The median IHC-score of YAP-1 in responders (CR/PR patients) was significantly lower than in nonresponders (SD/PD patients) at 13.97 (95% CI: 8.97-16.30) versus 23.72 (95% CI: 8.13-75.40)...the mPFS was 3.5 months (95%CI: 1.5–4.5 m) in the YAP-1 high group (H-score>22.00, n = 6) and 8.7 months (95%CI: 6.1–10.4 m) in the YAP-1 low group (H-score ≤22.00, n = 15), which were significantly different (P<0.05). (Fig. 3E)...our study indicated a negative correlation between the expression status of YAP-1 at the protein level and the efficacy of ECT in ES-SCLC patients...
Secondary therapy:
EC
DOI:
10.1016/j.ctarc.2023.100684
